Azelnidipine Down-Regulates Renal Angiotensin-Converting Enzyme and Mineralocorticoid Receptor mRNA in Diabetic Hypertensive Rats
Effects of a new lipophilic L-type calcium channel blocker, azelnidipine, on the expression of molecular components of the renin-angiotensin-aldosterone system (RAAS) were assessed. Male Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a model of diabetes with hypertension, and their lean littermates...
Main Authors: | Tetsuya Nakamura, Yuichiro Saito, Tomoko Saito, Masahiko Kurabayashi |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2006-01-01
|
Series: | Journal of Pharmacological Sciences |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1347861319343993 |
Similar Items
-
Clinical use of azelnidipine in the treatment of hypertension in Chinese patients
by: Chen BL, et al.
Published: (2015-02-01) -
Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial
by: Takami T, et al.
Published: (2013-03-01) -
Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial
by: Takami T, et al.
Published: (2013-04-01) -
Role of Mineralocorticoid and Angiotensin Type 1 Receptors in the Paraventricular Nucleus in Angiotensin-Induced Hypertension
by: Sandra L. Burke, et al.
Published: (2021-03-01) -
Mineralocorticoid hypertension
by: Vishal Gupta
Published: (2011-01-01)